Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Transgastric endoscopic peritoneoscopy · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Whipple | EXPERIMENTAL | Patients with pancreatic cancer who will proceed to a Whipple procedure. |
| Name | Type | Description |
|---|---|---|
| Transgastric endoscopic peritoneoscopy. | PROCEDURE | Exploration of the abdominal area |
Inclusion Criteria: * Pancreatic Cancer undergoing staging laparoscopy * Staging or diagnostic laparoscopy in anyone needing enteral access Exclusion Criteria: * Lack of consent * Intra-abdominal adhesions precluding diagnostic laparoscopy
Top 20 of 69 competitors
Transgastric endoscopic peritoneoscopy is an investigational procedure being studied for use in pancreatic cancer. It involves abdominal exploration without incisions, potentially allowing doctors to examine the peritoneal cavity through the stomach wall. The procedure is in early clinical development, with one completed Phase 1 trial involving 20 patients in the United States.
Transgastric endoscopic peritoneoscopy does not target a specific molecular target. It is a surgical procedure that uses an endoscope passed through the stomach wall to explore the abdominal cavity. This approach may provide a less invasive method for staging or evaluating pancreatic cancer compared to traditional surgical exploration.
Stryker Corporation (NYSE: SYK) is the developer of Transgastric endoscopic peritoneoscopy. The company is investigating this procedure for potential use in pancreatic cancer. Stryker is a medical technology company, and this procedure is in early-stage clinical development.
Transgastric endoscopic peritoneoscopy is in Phase 1 clinical development. The single trial for this procedure was an early Phase 1 study, which has been completed. The procedure is investigational and has not been approved by regulatory authorities for clinical use.
Transgastric endoscopic peritoneoscopy has one completed clinical trial, NCT00427752, titled "Abdominal Exploration Without Incisions." This early Phase 1 study enrolled 20 participants with pancreatic cancer in the United States. The trial was uncontrolled, meaning there was no comparison group, and it has been completed.